规格: | 98% |
分子量: | 456.6 |
包装 | 价格(元) |
500ug | 电议 |
1mg | 电议 |
Background:
Glipizide-d11is intended for use as an internal standard for the quantification of glipizide by GC- or LC-MS. Glipizide is a hypoglycemic agent.1It inhibits ATP-sensitive potassium (KATP) channels in primary mouse pancreatic β cells (IC50= 6.4 nM). Glipizide induces insulin release from isolated rat pancreatic tissue with an EC50value of 40 nM.2Dietary administration of glipizide (5 mg/kg per day for 10 days) increases the number of insulin receptors on isolated and purified mouse liver plasma membranes.3It reduces plasma glucose and triglyceride, but not total cholesterol, levels and increases plasma insulin levels in a rat model of diabetes induced by a high-fat diet and streptozotocin when administered orally at a dose of 5 mg/kg.4Formulations containing glipizide have been used in the treatment of type 2 diabetes.
1.ZÜnkler, B.J., Lenzen, S., MÄnner, K., et al.Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cellsNaunyn-Schmiedebergs Arch. Pharmacol.337(2)225-230(1998) 2.Herchuelz, A., and Malaisse, W.J.Insulinotropic potency of glipizide in vitroDiabetologia309-310(1973) 3.Feinglos, M.N., and Lebovitz, H.E.Sulphonylureas increase the number of insulin receptorsNature276(5684)184-185(1978) 4.Srinivasan, K., Viswanad, B., Asrat, L., et al.Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screeningPharmacol. Res.52(4)313-320(2005)